Drug Profile


Alternative Names: LY 300046; LY 300046.HCl; LY 300082; PETT 1

Latest Information Update: 20 Dec 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medivir AB
  • Developer Eli Lilly; Medivir AB
  • Class Antiretrovirals
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 20 Dec 1999 No-Development-Reported for HIV-1 infections in Sweden (Unknown route)
  • 20 Dec 1999 No-Development-Reported for HIV-1 infections in USA (Unknown route)
  • 27 Feb 1996 Two in vitro studies have been added to the antimicrobial activities section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top